華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

VOLUNTARY ANNOUNCEMENT
FORMATION OF THE FUND

This is a voluntary announcement made by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**").

The Company hereby announces that China Resources Pharmaceutical (Chengdu) Enterprise Management Partnership (Limited Partnership) (華潤醫藥(成都)企業管理合夥企業(有限合夥)[1]) (as the general partner), China Resources Pharmaceutical Investment Company Limited (華潤醫藥投資有限公司, a wholly-owned subsidiary of the Company), China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司, a non-wholly owned subsidiary of the Company listed on the Shenzhen Stock Exchange (stock code: 300294)), Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司, a non-wholly owned subsidiary of the Company listed on the Shenzhen Stock Exchange (stock code: 000423)), China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司, a non-wholly owned subsidiary of the Company listed on the Shanghai Stock Exchange (stock code: 600062)), Jiangzhong Pharmaceutical Co., Ltd. (江中藥業股份有限公司, a non-wholly owned subsidiary of the Company listed on the Shanghai Stock Exchange (stock code: 600750)), Chengdu Runyao Industry Investment Partnership (Limited Partnership) (成都潤藥產業投資合夥企業(有限合夥)[1], an employee ownership platform held by the investment team of the Fund, which is an independent third party) and five other independent third parties (as limited partners) have proposed to enter into a limited partnership agreement (the "**Limited Partnership Agreement**") in relation to the establishment of a joint venture fund, tentatively named as China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) (華潤醫藥(成都)創新投資基金合夥企業(有限合夥)[1]) (the "**Fund**") with a proposed size of RMB1 billion for a total term of seven years. The proposed aggregate capital commitment of the Group will amount to approximately RMB245 million, representing approximately 24.5% of the total capital commitment of the Fund. It is expected that, upon establishment, the Fund will not be accounted for as a subsidiary of the Company. Shenzhen China Resources Capital Equity Investment Co., Ltd. (深圳市華潤資本股權投資有限公司) is expected to be entrusted as the fund manager of the Fund.

Note:

1 This limited partnership has not been established as of the date of this announcement and will be established upon completion of the relevant industrial and commercial registration procedures in China. The name of the limited partnership may be subject to change.

As of the date of this announcement, the Limited Partnership Agreement and related definitive documentation in relation to the establishment and implementation of the Fund have not been entered into by the parties and the Fund has not been formally formed.

It is expected that the Fund will be principally engaged in equity investment, venture capital and investment management activities, primarily in pharmaceutical and health industries and strategic emerging sectors. Taking into account the industrial policies and favourable measures of the Chengdu government, the Fund is expected to focus on investments in enterprises in the fields of chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine tonics, synthetic biology and other enterprises in strategic emerging sectors.

It is believed that the Group can make full use of the resources of the professional investment team in the Fund, and through the Fund, effectively control the risks involving mergers and acquisitions and innovation projects, ensure the quality of target companies and reserve high quality strategic project resources, and accelerate the Group's strategic mergers and acquisitions, thereby achieving its strategic goals in the pharmaceutical industry and enhancing the Group's medium and long-term sustainable development.

The proposed formation of the Fund is subject to the execution of the Limited Partnership Agreement and various conditions as set forth therein, and may or may not proceed. The Company will comply with the applicable requirements under the Listing Rules upon execution of the Limited Partnership Agreement as and if required. Shareholders and potential investors of the Company are reminded to exercise caution in dealing with the securities of the Company.

For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese versions shall prevail.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 17 July 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Tao Ran and Mdm. Deng Rong as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.